Anzeige
Mehr »
Samstag, 07.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1W1SJ | ISIN: US29664W1053 | Ticker-Symbol: 0ET
Tradegate
06.06.25 | 20:16
1,082 Euro
+1,50 % +0,016
1-Jahres-Chart
ESPERION THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
ESPERION THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
1,0701,11006.06.
1,0471,09506.06.

Aktuelle News zur ESPERION Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MoEsperion Therapeutics, Inc. - 8-K, Current Report9
14.05.Cascale Talks ESPR at Innovation Forum Sustainable Apparel Event in Amsterdam310NORTHAMPTON, MA / ACCESS Newswire / May 14, 2025 / Elisabeth von Reitzenstein, senior director of policy and public affairs at Cascale, recently took to the stage at Innovation Forum's Sustainable Apparel...
► Artikel lesen
12.05.Esperion Settles Patent Litigation With Micro Labs For Generic Nexletol8
12.05.Esperion Therapeutics, Inc.: Esperion Reaches Settlement Agreement with ANDA Filer Not to Market Generic Version of NEXLETOL (bempedoic acid) Prior to April 19, 2040204ANN ARBOR, Mich., May 12, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that it has entered into a settlement agreement with Micro Labs USA, Inc. and its affiliate Micro Labs Limited...
► Artikel lesen
09.05.HLS Therapeutics and Esperion partner to commercialise oral cardiovascular medicines8
08.05.Esperion Therapeutics, Inc.: Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)136ANN ARBOR, Mich., May 08, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on May 7, 2025, the Company granted 15 new employees 49,300 restricted stock units (RSUs) under Esperion's...
► Artikel lesen
08.05.HLS Therapeutics Inc: HLS Therapeutics forms partnership with Esperion3
08.05.Esperion and HLS partner to commercialize heart disease treatments in Canada4
ESPERION Aktie jetzt für 0€ handeln
08.05.Esperion Therapeutics, Inc. - 10-Q, Quarterly Report10
08.05.HLS Therapeutics partners with Esperion Therapeutics to commercialize NEXLETOL and NEXLIZET in Canada5
08.05.Esperion Therapeutics, Inc.: Esperion Partners with HLS Therapeutics to Commercialize NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) in Canada12
07.05.ESPR's Q1 Earnings Miss Estimates, Revenues Beat, Stock Down18
06.05.Esperion Q1 2025 slides: U.S. product sales surge 41% amid strategic expansion25
06.05.Esperion Therapeutics, Inc. - 8-K, Current Report2
06.05.Esperion Therapeutics, Inc.: Esperion Reports First Quarter 2025 Financial Results167- Q1 2025 Total Revenue of $65.0 Million, a Decrease of 53% Y/Y; Adjusting for One Time Milestone Received in Q1 2024, Total Revenue Grew 63% Y/Y - - Q1 2025 U.S. Net Product Revenue Grew 41% Y/Y...
► Artikel lesen
25.04.H.C. Wainwright maintains Buy on Esperion stock, $16 target26
24.04.Esperion stellt neue Behandlungskandidaten für PSC vor30
24.04.Esperion unveils novel PSC treatment candidates4
24.04.Esperion Therapeutics, Inc.: Esperion Unveils Promising Research Supporting Lead Development Candidates for Primary Sclerosing Cholangitis (PSC) at R&D Day 2025115- Expands Development Portfolio with Introduction of a Novel Program Targeting PSC - - Confirms Highly Specific Allosteric ACLY Inhibitor Shown to Reduce Liver Injury, Inflammation and Fibrosis Across...
► Artikel lesen
17.04.ESPR: EU startet neuen Ökodesign-Plan für nachhaltige Produkte22
Weiter >>
61 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,7